347 related articles for article (PubMed ID: 19801945)
61. Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.
Ravimohan S; Tamuhla N; Nfanyana K; Steenhoff AP; Letlhogile R; Frank I; MacGregor RR; Gross R; Weissman D; Bisson GP
Clin Infect Dis; 2016 Mar; 62(6):795-803. PubMed ID: 26611774
[TBL] [Abstract][Full Text] [Related]
62. Disseminated infections due to Immune Reconstitution Inflammatory Syndrome after highly active antiretroviral therapy--report of 3 cases from Nigeria.
Ogoina D; Adekunle V; Obiako R; Umar A; Akolawole M; Ovosi J
Pan Afr Med J; 2011; 9():38. PubMed ID: 22355437
[TBL] [Abstract][Full Text] [Related]
63. Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters.
Okroj M; Tedeschi R; Mancuso R; Brambilla L; Tourlaki A; Dillner J; Blom AM
Vaccine; 2011 Feb; 29(6):1129-34. PubMed ID: 21134448
[TBL] [Abstract][Full Text] [Related]
64. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.
Achenbach CJ; Harrington RD; Dhanireddy S; Crane HM; Casper C; Kitahata MM
Clin Infect Dis; 2012 Feb; 54(3):424-33. PubMed ID: 22095568
[TBL] [Abstract][Full Text] [Related]
65. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
[TBL] [Abstract][Full Text] [Related]
66. Steroids are a risk factor for Kaposi's sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection.
Fernández-Sánchez M; Iglesias MC; Ablanedo-Terrazas Y; Ormsby CE; Alvarado-de la Barrera C; Reyes-Terán G
AIDS; 2016 Mar; 30(6):909-14. PubMed ID: 26636923
[TBL] [Abstract][Full Text] [Related]
67. Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients.
da Silva TP; Giacoia-Gripp CBW; Schmaltz CA; Sant'Anna FM; Saad MH; Matos JA; de Lima E Silva JCA; Rolla VC; Morgado MG
BMC Infect Dis; 2017 Sep; 17(1):606. PubMed ID: 28874142
[TBL] [Abstract][Full Text] [Related]
68. Predictors of immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma: a case report.
Cattelan AM; Mattiolo A; Grassi A; Piano MA; Sasset L; Trevenzoli M; Zanovello P; Calabrò ML
Infect Agent Cancer; 2016; 11():5. PubMed ID: 26848307
[TBL] [Abstract][Full Text] [Related]
69. Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe.
Erlandson KM; Gudza I; Fiorillo S; Ndemera B; Schooley RT; Gwanzura L; Borok M; Campbell TB
Int J Infect Dis; 2014 Jul; 24():6-10. PubMed ID: 24769175
[TBL] [Abstract][Full Text] [Related]
70. Effects of Antiretroviral Therapy on Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Transmission Among HIV-Infected Zambian Children.
Olp LN; Minhas V; Gondwe C; Kankasa C; Wojcicki J; Mitchell C; West JT; Wood C
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26185193
[TBL] [Abstract][Full Text] [Related]
71. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
72. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
Hosseinipour MC; Kang M; Krown SE; Bukuru A; Umbleja T; Martin JN; Orem J; Godfrey C; Hoagland B; Mwelase N; Langat D; Nyirenda M; MacRae J; Borok M; Samaneka W; Moses A; Mngqbisa R; Busakhala N; Martínez-Maza O; Ambinder R; Dittmer DP; Nokta M; Campbell TB;
Clin Infect Dis; 2018 Jul; 67(2):251-260. PubMed ID: 29365083
[TBL] [Abstract][Full Text] [Related]
73. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
[TBL] [Abstract][Full Text] [Related]
74. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation.
Daly ML; Fogo A; McDonald C; Morris-Jones R
Clin Exp Dermatol; 2014 Jan; 39(1):7-12. PubMed ID: 23691969
[TBL] [Abstract][Full Text] [Related]
75. A novel mathematical model of AIDS-associated Kaposi's sarcoma: Analysis and optimal control.
Kaondera-Shava RF; Lungu E; Szomolay B
Biosystems; 2021 Feb; 200():104318. PubMed ID: 33309554
[TBL] [Abstract][Full Text] [Related]
76. A prospective study of clinical outcomes of HIV-associated and HIV-negative Kaposi sarcoma in Uganda.
Phipps W; Adams SV; Mooka P; Kafeero J; Sekitene S; Mubiru D; Nankoma J; Namirembe C; Okoche L; Namubiru EB; Kayemba S; Baker KK; Redman MW; Casper C; Orem J; Warren EH
AIDS; 2023 Jan; 37(1):51-59. PubMed ID: 36083142
[TBL] [Abstract][Full Text] [Related]
77. CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.
Caby F; Guiguet M; Weiss L; Winston A; Miro JM; Konopnicki D; Le Moing V; Bonnet F; Reiss P; Mussini C; Poizot-Martin I; Taylor N; Skoutelis A; Meyer L; Goujard C; Bartmeyer B; Boesecke C; Antinori A; Quiros-Roldan E; Wittkop L; Frederiksen C; Castagna A; Thurnheer MC; Svedhem V; Jose S; Costagliola D; Mary-Krause M; Grabar S;
Clin Infect Dis; 2021 Jul; 73(1):50-59. PubMed ID: 34370842
[TBL] [Abstract][Full Text] [Related]
78. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
[TBL] [Abstract][Full Text] [Related]
79. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
[TBL] [Abstract][Full Text] [Related]
80. Clinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana.
Cox CM; El-Mallawany NK; Kabue M; Kovarik C; Schutze GE; Kazembe PN; Mehta PS
Pediatr Blood Cancer; 2013 Aug; 60(8):1274-80. PubMed ID: 23487320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
